Clinical governance, SNLG and HTA


Clinical governance, SNLG and HTA

Economic evaluation based on RWE, RCT and decision models

This line of activity concerns the development of statistical analyses for cost-effectiveness, cost-utility and cost-minimization, an integral part of the HTA plant.

These analyses are conducted using different approaches depending on whether data from real practice (Real World Evidence, RWE), randomized controlled trials or literature reviews or meta-analyzes are available.

In the latter case, the information available is systematized to populate a decision model that allows one to explore uncertainty by mapping alternative scenarios and projecting them over time.

These analyses make it possible to attribute a profile of economic sustainability to a new technology, by comparing cost-effectiveness or cost-utility ratios with different reference thresholds.